Evogene Ltd (NASDAQ:EVGN)’s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.63 and traded as high as $1.60. Evogene shares last traded at $1.60, with a volume of 1 shares trading hands.
Separately, ValuEngine raised shares of Evogene from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
The stock’s 50 day moving average is $1.63 and its 200-day moving average is $1.71. The company has a debt-to-equity ratio of 0.06, a quick ratio of 10.14 and a current ratio of 10.14.
Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.35). The business had revenue of $0.19 million for the quarter. Evogene had a negative net margin of 1,193.65% and a negative return on equity of 37.62%.
An institutional investor recently bought a new position in Evogene stock. Eidelman Virant Capital bought a new stake in Evogene Ltd (NASDAQ:EVGN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 63,600 shares of the biotechnology company’s stock, valued at approximately $102,000. Eidelman Virant Capital owned 0.25% of Evogene at the end of the most recent quarter. 29.23% of the stock is owned by hedge funds and other institutional investors.
About Evogene (NASDAQ:EVGN)
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.
Featured Story: What is a Swap?
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.